Menu Back to Real-World-Evidence-Conference

Program Committee

  • Nancy A. Dreyer, PhD, MPH, FISPE
    Nancy A. Dreyer, PhD, MPH, FISPE Chief Scientific Officer Emerita, RW Strategies, IQVIA; President
    Dreyer Strategies LLC, United States
  • Steven A. Anderson, PhD
    Steven A. Anderson, PhD Director, Office of Biostatistics and Epidemiology, CBER
    FDA, United States
  • Dorothee  Bartels, PhD, MSc
    Dorothee Bartels, PhD, MSc Chief Digital Officer
    Aetion, Germany
  • Brian  Bradbury, DrSc, MA
    Brian Bradbury, DrSc, MA Vice President, Center for Observational Research
    Amgen, United States
  • Paul M. Coplan, DrSc, MBA, MSc, FISPE
    Paul M. Coplan, DrSc, MBA, MSc, FISPE VP, Medical Device Epidemiology & Real-World Data Analytics
    Johnson & Johnson, United States
  • Marni  Hall, PhD, MPH
    Marni Hall, PhD, MPH Vice President, Regulatory Science and Strategy
    IQVIA, United States
  • James  Harnett, PharmD, MS
    James Harnett, PharmD, MS Executive Director, Health Economics and Outcomes Research
    Regeneron Pharmaceuticals, Inc. , United States
  • Jingyu (Julia)  Luan, PhD
    Jingyu (Julia) Luan, PhD Senior Director, Global Regulatory Affairs, BioPharmaceuticals R&D
    AstraZeneca, United States
  • David  Martin, MD, MPH
    David Martin, MD, MPH Vice President, Clinical Safety and Risk Management
    Moderna, United States
  • Robert  Reynolds, DrSc, FISPE
    Robert Reynolds, DrSc, FISPE Vice President, Epidemiology & Patient-Centered Outcomes
    GSK, United States
  • Debra  Schaumberg, DrSc, MPH
    Debra Schaumberg, DrSc, MPH Vice President, Epidemiology & Head Strategic and Scientific Affairs
    Evidera | PPD, United States
  • Mark  Stewart, PhD
    Mark Stewart, PhD Vice President, Science Policy
    Friends of Cancer Research, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download